Article preview from "The Pink Sheet" July 28, 2009
The Obama administration's proposal to establish an executive
branch advisory council on Medicare payment issues may raise the
threat of government negotiations for Medicare Part D drug
prices. Read on...
Continue reading "Part D Price Negotiation Surfaces Again? IMAC Proposal Needs Close Read " »
The Health Care Reform Corner – From the editors of "The Pink Sheet"
What are policymakers and stakeholders in Washington saying and
doing about health care reform? In this periodic BioPharma Today
feature, the editors of "The Pink Sheet" and "The Pink Sheet" DAILY highlight some of the major developments chronicled in those publications.
Read today's features...
Continue reading "The Health Care Reform Corner – From the editors of "The Pink Sheet"" »
Click here to watch the video on CNBC
Editor's Note: For those of you who don’t regularly watch CNBC’s India affiliate, you may have missed PharmAsia News' own Vikas Dandekar on previous installments, but I thought I would forward the link to his interview this morning about the story he broke for PharmAsia News:
GMP Deviations Lead WHO To Issue "Notice Of Concern" To Matrix Labs; May Suspend Prequalified Anti-AIDS Products
Full story reprinted from PharmAsia News - July 24, 2009
MUMBAI - The Indian drug industry received another blow to its
reputation when the World Health Organization issued a "Notice of
Concern" to Hyderabad-based Matrix Labs, which is now 90 percent owned
by Mylan, the third-largest generic drug maker in the world. Read the whole story...
Continue reading "Direct from India: GMP Deviations Lead WHO To Issue "Notice Of Concern" To Matrix Labs" »
Article preview from IN VIVO July 28, 2009
What does Roche's privatization of Genentech mean for the companies'
business development organizations and current and future partners? We
recently sat down with the company's two business development chiefs to
find out. Read on...
Continue reading "Business Development at Roche and Genentech: An Interview with Joe McCracken and Dan Zabrowski" »
Full article reprinted from The RPM Report July 28, 2009
A common theme for reform advocates in 2009 is avoiding the mistakes
that doomed the Clinton health care reform effort 15 years ago. The
biggest lesson of all is that the consequences of failure would be
critical to the Obama Administration. Read more...
Continue reading "The Long Shadow of HillaryCare" »
The Asia Corner - From the Editors of PharmAsia News July 28, 2009
In this BioPharma Today feature, the editors of PharmAsia News take a closer look each week at the most important biopharma developments from China, India, Japan, and the Pacific Rim.
Read today's features...
Continue reading "The Asia Corner - From the Editors of PharmAsia News" »
Full article reprinted "The Pink Sheet" DAILY July 28, 2009
On May 14, Millennium Pharmaceuticals marked its one-year anniversary as the Takeda Oncology company.
The biotech's acquisition by the Japanese pharma for $8.8 billion freed Millennium from demonstrating to Wall Street regular quarterly earnings at a time when the company was dependent on sales of its only product, the first-in-class protease inhibitor Velcade (bortezomib) ('The Pink Sheet' DAILY, April 10, 2008). Read on...
Continue reading ""A Quantum Leap In Resources": Millennium CEO Dunsire In A Conversation On The Firm's First Year As Part Of Takeda (Pt. 1 Of 2) " »
Full article reprinted from The RPM Report July 21, 2009
FDA is entering a new era of refined regulatory tools and an expanded regulatory umbrella that includes tobacco products. Drug manufacturers have witnessed a more activist FDA compared to the previous administration under the leadership team of Commissioner Margaret Hamburg and Deputy Commissioner Joshua Sharfstein.
Hamburg addressed a variety of issues during a press briefing including whether the agency will revisit drug safety decisions that left some riskier drugs on the market, the impact of tobacco regulation on drug and biotech regulatory operations, FDA’s drug marketing and promotion policy, and her working relationship with Sharfstein, among other issues. Read more...
Continue reading "Margaret Hamburg: The Public Health Commissioner" »
Article preview from IN VIVO July 21, 2009
Emerging global markets are a hot topic in pharmaceutical circles these days, but until recently, most Westerners viewed them as a homogenous cluster. Few executives at corporate headquarters drew distinctions among the various countries, let alone the domestic and international players in those markets. As big pharma bumps up against growth constraints in its traditional markets, however, interest in the "rest of the world" is perking up. The largest pharmaceutical companies are all looking at the same promising half dozen or so emerging countries, but they are taking radically different approaches to tackling them and are moving at different paces. Read on...
Continue reading "Emerging Pharma Markets: Adapt, Diversify, and Persist " »
